Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Olmesartan medoxomil

Base Information Edit
  • Chemical Name:Olmesartan medoxomil
  • CAS No.:144689-63-4
  • Molecular Formula:C29H30N6O6
  • Molecular Weight:558.594
  • Hs Code.:2934990002
  • European Community (EC) Number:604-433-1
  • NSC Number:758924
  • UNII:6M97XTV3HD
  • DSSTox Substance ID:DTXSID9045924
  • Nikkaji Number:J689.130F
  • Wikidata:Q27888058
  • NCI Thesaurus Code:C47640
  • RXCUI:118463
  • Pharos Ligand ID:KUVPWHRXXN1N
  • ChEMBL ID:CHEMBL1200692
  • Mol file:144689-63-4.mol
Olmesartan medoxomil

Synonyms:5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346;Benicar;CS 866;CS-866;CS866;Medoxomil, Olmesartan;olmesartan medoxomil;Olmetec;Votum

Suppliers and Price of Olmesartan medoxomil
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • Usbiological
  • Olmesartan Medoxomil
  • 10mg
  • $ 312.00
  • TRC
  • Olmesartan medoxomil
  • 10mg
  • $ 50.00
  • TRC
  • Olmesartan medoxomil
  • 50mg
  • $ 85.00
  • TCI Chemical
  • Olmesartan Medoxomil >98.0%(HPLC)(T)
  • 1g
  • $ 78.00
  • TCI Chemical
  • Olmesartan Medoxomil >98.0%(HPLC)(T)
  • 5g
  • $ 233.00
  • Sigma-Aldrich
  • Olmesartan medoxomil ≥98% (HPLC)
  • 250mg
  • $ 375.00
  • Sigma-Aldrich
  • Olmesartan medoxomil United States Pharmacopeia (USP) Reference Standard
  • 100mg
  • $ 769.00
  • Sigma-Aldrich
  • Olmesartan medoxomil ≥98% (HPLC)
  • 50mg
  • $ 95.90
  • Sigma-Aldrich
  • Olmesartan medoxomil for system suitability European Pharmacopoeia (EP) Reference Standard
  • $ 190.00
  • Sigma-Aldrich
  • Olmesartan medoxomil European Pharmacopoeia (EP) Reference Standard
  • $ 190.00
Total 236 raw suppliers
Chemical Property of Olmesartan medoxomil Edit
Chemical Property:
  • Appearance/Colour:White to off-white crystalline powder 
  • Melting Point:180 °C 
  • Boiling Point:804.2 °C at 760 mmHg 
  • PKA:4.15±0.10(Predicted) 
  • Flash Point:440.2 °C 
  • PSA:162.16000 
  • Density:1.38 g/cm3 
  • LogP:4.17000 
  • Storage Temp.:-20°C Freezer 
  • Solubility.:DMSO: soluble20mg/mL, clear 
  • XLogP3:3.8
  • Hydrogen Bond Donor Count:2
  • Hydrogen Bond Acceptor Count:10
  • Rotatable Bond Count:11
  • Exact Mass:558.22268270
  • Heavy Atom Count:41
  • Complexity:969
Purity/Quality:

99.00% *data from raw suppliers

Olmesartan Medoxomil *data from reagent suppliers

Safty Information:
  • Pictogram(s): Xi 
  • Hazard Codes:Xi 
MSDS Files:

SDS file from LookChem

Useful:
  • Canonical SMILES:CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
  • Recent ClinicalTrials:Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT? in Essential Hypertension Control
  • Recent EU Clinical Trials:Seeking the ideal anti-hypertensive therapy in obesity-related hypertension. An open-label, single center, randomized clinical trial.
  • Recent NIPH Clinical Trials:An Exploratory Study of CS-3150 to Evaluate the Relation between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients with Essential Hypertension
  • Description Olmesartan medoxomil was launched in the US as benicar(R), an orally administered treatment for hypertension. Olmesartan, is a new selective and competitive nonpeptide angiotensin II type 1 receptor antagonist and potently inhibits the Ang.ll-induced pressor responses. The drug competitively inhibited binding of [125I1]-All to AT1 receptors in bovine adrenal cortical membranes, but had no effect on binding to AT2 receptors in bovine cerebellar membranes. In comparative clinical studies in patients with essential hypertension, olmesartan reduced sitting cuff diastolic blood pressure significantly more than losartan, valdesartan and ibesartan, while reductions in systolic blood pressure were similar for all treatments. Olmesartan medoxomil was also shown to reduce blood pressure significantly more effectively than losartan and the ACE inhibitor captopril and as effectively as the pbloker atenolol.
  • Uses Olmesartan medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. Olmesartan medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan has a dual method of elimination, with about 60% eliminated by the liver and the remainder by the kidney. In situations of impaired renal or hepatic function, the alternative excretion pathway can compensate for the compromised one. Olmesartan is not metabolized by the cytochrome P450 enzyme system and therefore has a low potential for metabolic drug interactions, a feature that may be of importance when treating patients on multiple drug regimens, such as the elderly. Olmesartan is well tolerated and has an excellent safety profile that is comparable to that of placebo. In addition, olmesartan provides 24-h blood pressure control with a once-daily dosing. In head-to-head studies, olmesartan delivered superior blood pressure reduction when compared with other angiotensin-II receptor antagonists at their recommended doses.
  • Clinical Use Angiotensin-II receptor antagonist: Hypertension
  • Drug interactions Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs. Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE-Is and aliskiren. Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity. Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics. ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect. Lithium: reduced excretion (possibility of enhanced lithium toxicity). Potassium salts: increased risk of hyperkalaemia. Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.
Technology Process of Olmesartan medoxomil

There total 55 articles about Olmesartan medoxomil which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:
Guidance literature:
With acetic acid; In water; at 25 ℃; for 1h;
Guidance literature:
trityl olmesartan medoxomil; With sulfuric acid; water; In acetone; at 40 ℃; for 2 - 4h;
With sodium hydrogencarbonate; at 20 ℃; for 1h;
Post RFQ for Price